Compare with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES NOVARTIS ALKEM LABORATORIES/
NOVARTIS
 
P/E (TTM) x - 512.7 - View Chart
P/BV x 6.6 29.7 22.3% View Chart
Dividend Yield % 0.7 1.5 42.4%  

Financials

 ALKEM LABORATORIES   NOVARTIS
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
NOVARTIS
Mar-18
ALKEM LABORATORIES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,589758 209.6%   
Low Rs1,232579 212.8%   
Sales per share (Unadj.) Rs417.5228.4 182.8%  
Earnings per share (Unadj.) Rs56.331.7 177.4%  
Cash flow per share (Unadj.) Rs64.732.8 197.5%  
Dividends per share (Unadj.) Rs12.7010.00 127.0%  
Dividend yield (eoy) %0.91.5 60.2%  
Book value per share (Unadj.) Rs292.9297.1 98.6%  
Shares outstanding (eoy) m119.5724.69 484.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.9 115.4%   
Avg P/E ratio x25.121.1 119.0%  
P/CF ratio (eoy) x21.820.4 106.8%  
Price / Book Value ratio x4.82.2 214.0%  
Dividend payout %22.631.5 71.6%   
Avg Mkt Cap Rs m168,65316,505 1,021.8%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m9,1711,445 634.6%   
Avg. sales/employee Rs ThNM8,441.3-  
Avg. wages/employee Rs ThNM2,163.6-  
Avg. net profit/employee Rs ThNM1,173.1-  
INCOME DATA
Net Sales Rs m49,9155,639 885.2%  
Other income Rs m1,6451,718 95.7%   
Total revenues Rs m51,5617,357 700.8%   
Gross profit Rs m8,482-63 -13,571.7%  
Depreciation Rs m1,00625 3,975.5%   
Interest Rs m67155 1,212.7%   
Profit before tax Rs m8,4511,575 536.5%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606792 202.9%   
Profit after tax Rs m6,731784 859.0%  
Gross profit margin %17.0-1.1 -1,533.2%  
Effective tax rate %19.050.3 37.8%   
Net profit margin %13.513.9 97.0%  
BALANCE SHEET DATA
Current assets Rs m27,0629,522 284.2%   
Current liabilities Rs m15,3243,296 464.9%   
Net working cap to sales %23.5110.4 21.3%  
Current ratio x1.82.9 61.1%  
Inventory Days Days6737 181.6%  
Debtors Days Days4128 145.2%  
Net fixed assets Rs m12,61046 27,412.0%   
Share capital Rs m239123 193.8%   
"Free" reserves Rs m34,4907,213 478.2%   
Net worth Rs m35,0277,336 477.4%   
Long term debt Rs m1,2120-   
Total assets Rs m54,38711,105 489.7%  
Interest coverage x13.629.5 46.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.5 180.8%   
Return on assets %13.67.6 180.2%  
Return on equity %19.210.7 179.9%  
Return on capital %24.922.2 111.8%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56361 10,830.5%   
Fx outflow Rs m3,0123,630 83.0%   
Net fx Rs m3,552-3,570 -99.5%   
CASH FLOW
From Operations Rs m7,2591,610 450.9%  
From Investments Rs m1,864687 271.4%  
From Financial Activity Rs m-9,273-2,677 346.4%  
Net Cashflow Rs m-150-380 39.5%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 33.1 2.0 1,655.0%  
FIIs % 0.0 1.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 21.5 -  
Shareholders   68,381 41,647 164.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   CIPLA  PFIZER  DR. DATSONS LABS  SHASUN PHARMA  SANOFI INDIA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS